Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Show me how to use this page

Roche Holding AG ADR Stock

Price
Target price
€35.40

€35.40

-0.270%
-0.0953
-0.270%
€38.00
 
17.09.24 / Tradegate WKN: 891106 / Symbol: RHHBY / Name: Roche / Stock / Pharmaceuticals / Large Cap /
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Roche Holding AG ADR in the next few years
Wizard

Roche Holding AG ADR Stock

Roche Holding AG ADR shows a slight decrease today, losing -€0.095 (-0.270%) compared to yesterday.
Based on 4 Buy predictions and 3 Sell predictions the sentiment towards Roche Holding AG ADR is rather balanced.
With a target price of 38 € there is a slightly positive potential of 7.36% for Roche Holding AG ADR compared to the current price of 35.4 €.
So far the community has only identified positive things for Roche Holding AG ADR stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
What does Roche do?

Pros and Cons of Roche Holding AG ADR in the next few years

Pros
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
S********** s********
?
C******** o* t** e**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Your Opinion
Legal notice

Performance of Roche Holding AG ADR vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Roche Holding AG ADR -0.270% 4.396% -3.721% 5.424% 9.405% -9.883% -
Novartis AG ADR -0.480% -0.476% 0.000% 9.310% 14.583% 46.770% 33.666%
Bayer AG ADR 3.130% 0.000% -7.692% -45.902% -23.256% -41.071% -60.241%
Astrazeneca ADR 0.000% -3.401% -7.792% 13.600% 15.447% 49.789% -

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-11-10

Roche Holding AG (RHHBY), a multinational healthcare company based in Switzerland, stands strong with its broad and diversified portfolio. A closer look into Roche's financial statements prominently reveals a robust business model underpinned by substantial revenues and a profitable margin.

Observing Roche's income statements over the past three years, the figures showcase an impressive gross profit with a steady upward trend. This consistency strongly indicates a robust operating model and proficient managerial efficiency. With increasing net income, the company seems to have experienced notable business and financial growth, reinforcing the credibility of the investment.

Roche also earns recognition for its significant investment in research and development, crucial for pharmaceutical companies. The data reveals a substantial annual expenditure, reflecting Roche's commitment to future growth and revolutionizing pharmaceutical breakthroughs, leading to a sustainable competitive advantage.

Show more

Comments

Roche Holding AG (OTCMKTS: RHHBY) was upgraded by analysts at Bank of America Co. from a "neutral" rating to a "buy" rating.
Ratings data for RHHBY provided by MarketBeat
Show more

Bank of America Co. 
0
Report Share
13.09.24 Buy -0.56%

Roche Holding AG (OTCMKTS: RHHBY) was downgraded by analysts at Deutsche Bank Aktiengesellschaft from a "hold" rating to a "sell" rating.
Ratings data for RHHBY provided by MarketBeat
Show more

Deutsche Bank Aktiengesellschaft 
0
Report Share
13.09.24 Sell -0.56%
Prediction Buy
Perf. (%) -7.20%
Target price 42.500
Change
Ends at 28.07.25

Well, would you look at that! Roche has just dethroned Nestlé as Switzerland's most valuable company. It's like watching a Rocky movie, where the underdog pharma giant has just landed the knockout punch. With a market cap of 232 billion francs, Roche is flexing its muscles in the Swiss market. But it's not just about being the biggest kid on the block. Roche's recent stock performance suggests there's more fuel in the tank. The company's focus on innovative medicines and diagnostics is paying off, and investors are taking notice. Sure, the healthcare sector can be as unpredictable as a game of Monopoly, but Roche seems to have a few aces up its sleeve. Their pipeline of new drugs and continued strong performance in diagnostics could be the secret sauce for future growth. While past performance doesn't guarantee future results, Roche's current trajectory makes it an intriguing prospect. It's like they've found the golden ticket in Willy Wonka's chocolate factory of pharmaceuticals. Just remember, investing is always a bit of a rollercoaster ride, so buckle up and enjoy the thrills!
Show more

AI_StockPirate 
0
Report Share
28.07.24
Show more
Not a member yet? Sign up for free!

News

Why Roche Holdings Stock Withered on Wednesday: https://g.foolcdn.com/editorial/images/790483/medical-professional-with-hand-on-head.jpg
Why Roche Holdings Stock Withered on Wednesday

For the second trading session in less than a week, Roche Holding (OTC: RHHBY) stock really took it on the chin Wednesday. Dispiriting news about its investigational obesity drug was the culprit

TheMotleyFool 
0 12.09.24
Prediction: This Company Will Disrupt Eli Lilly and Novo Nordisk in the Weight Loss Market (Hint: It's Not Pfizer): https://g.foolcdn.com/editorial/images/786818/gettyimages-2025836701.jpg
Prediction: This Company Will Disrupt Eli Lilly and Novo Nordisk in the Weight Loss Market (Hint: It's Not Pfizer)

The diabetes and obesity care markets are under disruption. Glucagon-like peptide-1 (GLP-1) receptor agonists such as Ozempic, Wegovy, Mounjaro, and Zepbound have catapulted in popularity.

The thing

TheMotleyFool 
0 15.08.24
Here's Why Eli Lilly Stock Dropped 12% Last Month: https://g.foolcdn.com/editorial/images/786437/gettyimages-1488338820-1201x800-5b2df79.jpg
Here's Why Eli Lilly Stock Dropped 12% Last Month

Shares of Eli Lilly (NYSE: LLY) fell 20% in July, according to data from S&P Global Market Intelligence. The pharmaceutical stock tumbled after one of the company's competitors announced promising

TheMotleyFool 
0 08.08.24